心血管疾病与2型糖尿病:新时代的曙光已经到来?
高血糖是2型糖尿病微血管并发症的主要危险因素,但心血管疾病是主要死因,降低HbA1c对降低心血管风险作用有限。LEADER和SUSTAIN-6试验显示利拉鲁肽和司美格鲁肽分别降低主要不良心血管事件(MACE)13%和24%;EMPA-REG OUTCOME、IRIS和PROactive研究也显示恩格列净和吡格列酮显著减少心血管事件,但各药对MACE各组分的影响不同,提示机制不同,联合使用可能带来叠加或倍增的心血管获益。
要点
- 利拉鲁肽和司美格鲁肽在伴有高心血管风险的2型糖尿病患者中分别降低MACE 13%和24%。
- 恩格列净和吡格列酮在相应研究中显示显著减少心血管事件。
- 四种降糖药对MACE三个组分的影响不同,提示心血管获益机制不同。
核心结论
- 利拉鲁肽、司美格鲁肽、吡格列酮和恩格列净虽均降低血糖,但似乎通过不同机制降低心血管风险,联合使用可能具有叠加或倍增的心血管获益。
研究设计与样本
- 本文为综述,总结LEADER、SUSTAIN-6、EMPA-REG OUTCOME、IRIS和PROactive等研究的结果。
主要发现
- 在伴有高心血管风险的2型糖尿病患者中,利拉鲁肽降低主要不良心血管事件(MACE,包括心血管死亡、非致死性心肌梗死、非致死性卒中)13%,司美格鲁肽降低24%。
- EMPA-REG OUTCOME、IRIS(非糖尿病患者)和PROactive(第二主要终点)研究显示,恩格列净和吡格列酮治疗显著减少2型糖尿病患者的心血管事件。
- 四种降糖药对MACE三个组分的影响存在差异,提示不同机制参与心血管事件减少。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively. The EMPA-REG OUTCOME, IRIS (subjects without diabetes), and PROactive (second principal end point) studies also demonstrated a significant reduction in cardiovascular events in T2D patients treated with empagliflozin and pioglitazone. However, the benefit of these four antidiabetes agents (liraglutide, semaglutide, empagliflozin, and pioglitazone) on the three individual MACE end points differed, suggesting that different underlying mechanisms were responsible for the reduction in cardiovascular events. Since liraglutide, semaglutide, pioglitazone, and empagliflozin similarly lower the plasma glucose concentration but appear to reduce CVD risk by different mechanisms, there emerges the intriguing possibility that, if used in combination, the effects of these antidiabetes agents may be additive or even multiplicative with regard to cardiovascular benefit.
引用
- Abdul-Ghani M, DeFronzo RA, Del Prato S, et al. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care. 2017. PMID: 28637886. doi:10.2337/dc16-2736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。